Project Grant K22CA288779
Award Date 8/13/26
Completion Date 7/31/29
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $144,035 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting transcription factor-mediated chromatin remodeling complex activities in human cancer. The funded work integrates biochemistry, structural biology, functional genomics, and chemical biology approaches to define how BAF (mammalian SWI/SNF) chromatin remodeling complexes are recruited by transcription...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $134,919 on April 14, 2026, under the Cancer Research Manpower program (CFDA 93.398) to establish ethical standards for informed consent and counseling in multi-cancer early detection testing. Dr. Eric Blackstone, a bioethics research fellow, will conduct three coordinated research aims. Aim 1 evaluates patient comprehension of key multi-cancer early detection information and patient experiences with informed consent and...
- The National Cancer Institute awarded the Trustees of Boston University $110,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research defining the landscape of whole-genome doubling across mammalian tissues. The recipient will use a transgenic cell-cycle reporter mouse model to identify, purify, and manipulate whole-genome doubling (WGD) cells from murine tissues. The research comprises two aims: quantifying how WGD-positive cells accumulate with...
- The National Cancer Institute awarded The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, $245,297 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop chimeric molecules that trigger generation of neoantigens from proteins dysregulated in infectious disease and cancer. The molecules will be formed by joining clinical-grade protein binders with reactive groups to generate neoantigens that recruit immune system...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...